Safety and efficacy of adalimumab in pediatric patients with Crohn disease.

Safety and efficacy of adalimumab in pediatric patients with Crohn disease.

Item
http://www.wikidata.org/entity/Q37209471
Anaphylaxis: mechanisms and management.The development and assessment of biological treatments for children.Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseThe London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Adalimumab for the treatment of pediatric Crohn's disease.Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab.A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease.Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
P2860

Safety and efficacy of adalimumab in pediatric patients with Crohn disease.

Item
http://www.wikidata.org/entity/Q37209471
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
@en
Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
@nl
type
label
Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
@en
Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
@nl
prefLabel
Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
@en
Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
@en
P2093
P304
P31
P356
10.1097/MPG.0B013E318174E886
P407
P433
P478
P577
P698
P921